FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1497170016> ?p ?o ?g. }

• W1497170016 endingPage "2296" @default.
• W1497170016 startingPage "2283" @default.
• W1497170016 abstract "Despite declines in morbidity and mortality with the use of combination antiretroviral therapy, its effectiveness is limited by adverse events, problems with adherence, and resistance of the human immunodeficiency virus (HIV).We randomly assigned persons infected with HIV who had a CD4+ cell count of more than 350 per cubic millimeter to the continuous use of antiretroviral therapy (the viral suppression group) or the episodic use of antiretroviral therapy (the drug conservation group). Episodic use involved the deferral of therapy until the CD4+ count decreased to less than 250 per cubic millimeter and then the use of therapy until the CD4+ count increased to more than 350 per cubic millimeter. The primary end point was the development of an opportunistic disease or death from any cause. An important secondary end point was major cardiovascular, renal, or hepatic disease.A total of 5472 participants (2720 assigned to drug conservation and 2752 to viral suppression) were followed for an average of 16 months before the protocol was modified for the drug conservation group. At baseline, the median and nadir CD4+ counts were 597 per cubic millimeter and 250 per cubic millimeter, respectively, and 71.7% of participants had plasma HIV RNA levels of 400 copies or less per milliliter. Opportunistic disease or death from any cause occurred in 120 participants (3.3 events per 100 person-years) in the drug conservation group and 47 participants (1.3 per 100 person-years) in the viral suppression group (hazard ratio for the drug conservation group vs. the viral suppression group, 2.6; 95% confidence interval [CI], 1.9 to 3.7; P<0.001). Hazard ratios for death from any cause and for major cardiovascular, renal, and hepatic disease were 1.8 (95% CI, 1.2 to 2.9; P=0.007) and 1.7 (95% CI, 1.1 to 2.5; P=0.009), respectively. Adjustment for the latest CD4+ count and HIV RNA level (as time-updated covariates) reduced the hazard ratio for the primary end point from 2.6 to 1.5 (95% CI, 1.0 to 2.1).Episodic antiretroviral therapy guided by the CD4+ count, as used in our study, significantly increased the risk of opportunistic disease or death from any cause, as compared with continuous antiretroviral therapy, largely as a consequence of lowering the CD4+ cell count and increasing the viral load. Episodic antiretroviral therapy does not reduce the risk of adverse events that have been associated with antiretroviral therapy. (ClinicalTrials.gov number, NCT00027352 [ClinicalTrials.gov].)." @default.
• W1497170016 created "2016-06-24" @default.
• W1497170016 creator A5001303096 @default.
• W1497170016 creator A5002944906 @default.
• W1497170016 creator A5004079054 @default.
• W1497170016 creator A5004174170 @default.
• W1497170016 creator A5006623516 @default.
• W1497170016 creator A5010009356 @default.
• W1497170016 creator A5011895210 @default.
• W1497170016 creator A5020940696 @default.
• W1497170016 creator A5029861967 @default.
• W1497170016 creator A5030905646 @default.
• W1497170016 creator A5031838283 @default.
• W1497170016 creator A5032506073 @default.
• W1497170016 creator A5037765362 @default.
• W1497170016 creator A5038042506 @default.
• W1497170016 creator A5042823176 @default.
• W1497170016 creator A5052799278 @default.
• W1497170016 creator A5062744631 @default.
• W1497170016 creator A5063673979 @default.
• W1497170016 creator A5064026329 @default.
• W1497170016 creator A5064663288 @default.
• W1497170016 creator A5068114811 @default.
• W1497170016 creator A5072399138 @default.
• W1497170016 creator A5088502098 @default.
• W1497170016 creator A5089346808 @default.
• W1497170016 date "2006-11-30" @default.
• W1497170016 modified "2023-10-14" @default.
• W1497170016 title "CD4+ Count–Guided Interruption of Antiretroviral Treatment" @default.
• W1497170016 cites W1497870368 @default.
• W1497170016 cites W1956661292 @default.
• W1497170016 cites W1970964138 @default.
• W1497170016 cites W1976828027 @default.
• W1497170016 cites W1978444406 @default.
• W1497170016 cites W1983105031 @default.
• W1497170016 cites W1995935850 @default.
• W1497170016 cites W1998660799 @default.
• W1497170016 cites W2000333987 @default.
• W1497170016 cites W2001096404 @default.
• W1497170016 cites W2001634163 @default.
• W1497170016 cites W2040455320 @default.
• W1497170016 cites W2041929815 @default.
• W1497170016 cites W2051269276 @default.
• W1497170016 cites W2059707463 @default.
• W1497170016 cites W2068559235 @default.
• W1497170016 cites W2073831371 @default.
• W1497170016 cites W2080237955 @default.
• W1497170016 cites W2091326103 @default.
• W1497170016 cites W2099509337 @default.
• W1497170016 cites W2108719992 @default.
• W1497170016 cites W2126633107 @default.
• W1497170016 cites W2129630483 @default.
• W1497170016 cites W2147126755 @default.
• W1497170016 cites W2157138119 @default.
• W1497170016 cites W2159686293 @default.
• W1497170016 cites W2169085525 @default.
• W1497170016 cites W2294450137 @default.
• W1497170016 cites W2314841159 @default.
• W1497170016 cites W2318289184 @default.
• W1497170016 cites W2334322250 @default.
• W1497170016 cites W2977606681 @default.
• W1497170016 cites W4242589154 @default.
• W1497170016 cites W4243961932 @default.
• W1497170016 doi "https://doi.org/10.1056/nejmoa062360" @default.
• W1497170016 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17135583" @default.
• W1497170016 hasPublicationYear "2006" @default.
• W1497170016 type Work @default.
• W1497170016 sameAs 1497170016 @default.
• W1497170016 citedByCount "1983" @default.
• W1497170016 countsByYear W14971700162012 @default.
• W1497170016 countsByYear W14971700162013 @default.
• W1497170016 countsByYear W14971700162014 @default.
• W1497170016 countsByYear W14971700162015 @default.
• W1497170016 countsByYear W14971700162016 @default.
• W1497170016 countsByYear W14971700162017 @default.
• W1497170016 countsByYear W14971700162018 @default.
• W1497170016 countsByYear W14971700162019 @default.
• W1497170016 countsByYear W14971700162020 @default.
• W1497170016 countsByYear W14971700162021 @default.
• W1497170016 countsByYear W14971700162022 @default.
• W1497170016 countsByYear W14971700162023 @default.
• W1497170016 crossrefType "journal-article" @default.
• W1497170016 hasAuthorship W1497170016A5001303096 @default.
• W1497170016 hasAuthorship W1497170016A5002944906 @default.
• W1497170016 hasAuthorship W1497170016A5004079054 @default.
• W1497170016 hasAuthorship W1497170016A5004174170 @default.
• W1497170016 hasAuthorship W1497170016A5006623516 @default.
• W1497170016 hasAuthorship W1497170016A5010009356 @default.
• W1497170016 hasAuthorship W1497170016A5011895210 @default.
• W1497170016 hasAuthorship W1497170016A5020940696 @default.
• W1497170016 hasAuthorship W1497170016A5029861967 @default.
• W1497170016 hasAuthorship W1497170016A5030905646 @default.
• W1497170016 hasAuthorship W1497170016A5031838283 @default.
• W1497170016 hasAuthorship W1497170016A5032506073 @default.
• W1497170016 hasAuthorship W1497170016A5037765362 @default.
• W1497170016 hasAuthorship W1497170016A5038042506 @default.
• W1497170016 hasAuthorship W1497170016A5042823176 @default.
• W1497170016 hasAuthorship W1497170016A5052799278 @default.

• next